Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.

  title={Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.},
  author={Julie Berg Schmidt and Nikolaj Ture Gregersen and Sue D. Pedersen and Johanne Louise Arentoft and Christian Ritz and Thue W. Schwartz and Jens Juul Holst and Arne Astrup and Anders M. Sj{\"o}din},
  journal={American journal of physiology. Endocrinology and metabolism},
  volume={306 11},
Our aim was to examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin, and vital signs in healthy overweight men. Twenty-five healthy male subjects participated in this randomized, double-blinded, placebo-controlled, four-arm crossover study (BMI 29 ± 3 kg/m(2), age 33 ± 9 yr). On separate days they received a 150-min intravenous infusion of 1) 0.8 pmol·kg(-1)·min(-1) PYY3-36, 2) 1.0… 

Figures and Tables from this paper

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure.

CONTEXT The gut hormone, oxyntomodulin, is a proglucagon product with body weight-lowering potential. It binds to both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor; however,

Serum lipase activity and concentration during intravenous infusions of GLP‐1 and PYY 3‐36 and after ad libitum meal ingestion in overweight men

Serum lipase levels measured by enzyme‐linked immunosorbent assay (ELISA) following mono‐infusions of GLP‐1 and PYY3‐36 were comparable to serumlipase levels following placebo, and a small increase in serum lipase may occur in response to a meal.

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers

This is the first time that an acute continuous subcutaneous infusion of GOP, replicating the postprandial levels observed after RYGB, is shown to be safe and effective in reducing food intake, and suggests that triple hormone therapy might be a useful tool against obesity.

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study

GOP infusion improves glycemia and reduces body weight and achieves superior glucose tolerance and reduced glucose variability compared with RYGB and VLCD, and is a viable alternative for the treatment of diabetes with favorable effects on body weight.

A high carbohydrate, but not fat or protein meal attenuates postprandial ghrelin, PYY and GLP-1 responses in Chinese men

A high-protein or high-fat meal induces a more favorable postprandial satiety and appetite hormonal response than a high-carbohydrate meal in obese insulin-resistant subjects.

Do Lactation-Induced Changes in Ghrelin, Glucagon-Like Peptide-1, and Peptide YY Influence Appetite and Body Weight Regulation during the First Postpartum Year?

Overall these studies do not support the hypothesis that appetite-regulating hormones are altered during lactation and associated with postpartum weight retention; altered ghrelin responses, however, deserve further exploration.

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

Combined blockade of GLP-1 and PYY actions increased food intake after RYGB, supporting that these hormones have a role in decreased food intake postoperatively and probably explaining the absent effect on food intake on these experimental days.



Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects.

Peptide YY (PYY)(3-36) has been shown to produce dramatic reductions in energy intake (EI), but no human data exist regarding energy expenditure (EE), glucose and fat metabolism. Nothing is known

Effect of peptide YY3-36 on food intake in humans.

This study shows that intravenous infusions of PYY3-36 decrease spontaneous food intake; the inhibition is, however, only significant at pharmacologic plasma concentrations.

Attenuated peptide YY release in obese subjects is associated with reduced satiety.

Obese subjects have a PYY deficiency that would reduce satiety and could thus reinforce their obesity, and fasting and postprandial endogenous plasma PYY levels were attenuated in obese humans and rodents.

Inhibition of food intake in obese subjects by peptide YY3-36.

It is found that obese subjects were not resistant to the anorectic effects of PYY, and endogenous PYY levels were low in obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.

Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.

PYY(3-36) and GLP-1(7-36), cosecreted after a meal, may inhibit food intake additively and is studied in rodents and man.

Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.

A marked effect of orally administered GLP-1 and PYY3-36 on appetite is shown by showing enhanced fullness at meal onset and reduced energy intake, with marked effects on glucose homeostasis.

Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice.

It is suggested that administration of low doses of Ex4 together with PYY(3-36NH2) may increase the suppression of FI without inducing significant side effects, and this work confirms that cosecreted peptides regulate food intake in rodents and humans via independent mechanisms.

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

The aim was to examine the effect of glucagon-like peptide-1 on subsequent energy intake using a data set composed of subject data from previous studies and from two as yet unpublished studies, and investigate whether the effect on energy intake is dose dependent and differs between lean and overweight subjects.